| Title: |
Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages |
| Authors: |
Fuster-Anglada, Carla; Corominas, Josep; Marsal, Aida; Llarch, Neus; Iserte, Gemma; Sanduzzi-Zamparelli, Marco; Forner, Alejandro; Ferrer-Fábrega, Joana; Holguin, Victor; Morales, Albert; Saavedra, Carolina; Reig, Maria; Boix, Loreto; Marí, Montserrat; Díaz, Alba |
| Contributors: |
Instituto de Salud Carlos III; Agencia Estatal de Investigación (España); Ministerio de Ciencia e Innovación (España); Ministerio de Ciencia, Innovación y Universidades (España); European Commission; Marí, Montserrat; Consejo Superior de Investigaciones Científicas https://ror.org/02gfc7t72 |
| Publisher Information: |
Frontiers Media |
| Publication Year: |
2025 |
| Collection: |
Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| Subject Terms: |
NK cells; Hepatocellular carcinoma; Immune exhaustion; Lymphocytes; Sorafenib |
| Description: |
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy. However, their efficacy in hepatocellular carcinoma (HCC) is limited, highlighting the need to further explore immune microenvironments and novel biomarkers. This study examined lymphocyte populations and immune checkpoint dynamics in early, advanced, and post-progression HCC to better understand immune dynamics in HCC and to help identify predictive biomarkers and immune modulation strategies. ; The author(s) declare that financial support was received for the research and/or publication of this article. Premi final de residencia “Emili Letang-Josep Font” to CF-A. This research was funded by Instituto de Salud Carlos III (ISCIII) through projects PI22/01427 to MR, PI22/00475 to MM, MCIN/AEI/10.13039/501100011033, PID2021-123564OB-100 and PDC2023-145806–100 to AM, and co-funded by NextGenerationEU/PRTR, and by “ERDF A way of making Europe”; CIBEREHD; MSZ: received grant support from Instituto de Salud Carlos III (FI19/00222) and from CIBEREHD (CIBER/EHD25PI02). ; Peer reviewed |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
#PLACEHOLDER_PARENT_METADATA_VALUE#; info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-123564OB-I00/ES/TERAPIAS DIRIGIDAS BASADAS EN EL PERFIL MOLECULAR: MITOCONDRIA Y EJE GAS6%2FTAM EN CROSSTALK CELULAR/; info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PDC2023-145806-I00/ES/BIOPLATAFORMA BASADA EN LA FIRMA SERICA DEL SECRETOMA HEPATICO COMO HERRAMIENTA PRONOSTICA PARA EL TRATAMIENTO DEL CARCINOMA HEPATOCELULAR/; The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.3389/fimmu.2025.1611365; https://doi.org/10.3389/fimmu.2025.1611365; Sí; Frontiers in Immunology 16: 1611365 (2025); https://hdl.handle.net/10261/403692; http://dx.doi.org/10.13039/501100011033; http://dx.doi.org/10.13039/501100004837; http://dx.doi.org/10.13039/501100004587; http://dx.doi.org/10.13039/501100000780; https://api.elsevier.com/content/abstract/scopus_id/105008726106 |
| DOI: |
10.3389/fimmu.2025.1611365 |
| DOI: |
10.13039/501100011033 |
| DOI: |
10.13039/501100004837 |
| DOI: |
10.13039/501100004587 |
| DOI: |
10.13039/501100000780 |
| Availability: |
https://hdl.handle.net/10261/403692; https://doi.org/10.3389/fimmu.2025.1611365; https://doi.org/10.13039/501100011033; https://doi.org/10.13039/501100004837; https://doi.org/10.13039/501100004587; https://doi.org/10.13039/501100000780; https://api.elsevier.com/content/abstract/scopus_id/105008726106 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.611DF7F1 |
| Database: |
BASE |